{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "regularMarketChangePercent": 0.0, "regularMarketPrice": 21.885, "exchange": "PNK", "shortName": "SWEDISH ORPHAN BIOVITRUM AB", "longName": "Swedish Orphan Biovitrum AB (publ)", "messageBoardId": "finmb_1072270", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1610116200000, "tradeable": false, "cryptoTradeable": false, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683748733, "regularMarketDayHigh": 21.885, "regularMarketDayRange": "21.885 - 21.885", "regularMarketDayLow": 21.885, "regularMarketVolume": 10, "regularMarketPreviousClose": 21.885, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Other OTC", "financialCurrency": "SEK", "regularMarketOpen": 22.15, "averageDailyVolume3Month": 126, "averageDailyVolume10Day": 170, "fiftyTwoWeekLowChange": 3.6350002, "fiftyTwoWeekLowChangePercent": 0.1991781, "fiftyTwoWeekRange": "18.25 - 26.48", "fiftyTwoWeekHighChange": -4.5949993, "fiftyTwoWeekHighChangePercent": -0.17352717, "fiftyTwoWeekLow": 18.25, "fiftyTwoWeekHigh": 26.48, "trailingAnnualDividendRate": 0.0, "trailingPE": 21.04327, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 1.04, "sharesOutstanding": 296614016, "fiftyDayAverage": 23.88364, "fiftyDayAverageChange": -1.9986401, "fiftyDayAverageChangePercent": -0.08368239, "twoHundredDayAverage": 21.67603, "twoHundredDayAverageChange": 0.20897102, "twoHundredDayAverageChangePercent": 0.009640651, "marketCap": 6491397632, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "symbol": "BIOVF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Tomtebodav\u00e4gen 23A", "city": "Solna", "zip": "112 76", "country": "Sweden", "phone": "46 86 97 20 00", "website": "https://www.sobi.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli\u00ae/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.", "fullTimeEmployees": 1612, "companyOfficers": [{"maxAge": 1, "name": "Dr. Guido  Oelkers", "age": 57, "title": "CEO & Pres", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Henrik  Stenqvist", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Torbj\u00f6rn  Hallberg", "age": 53, "title": "Gen. Counsel and Head of Legal Affairs & HR", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel  Rankin", "age": 42, "title": "Head of Strategy & Corp. Devel.", "yearBorn": 1980, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Pablo  de Mora", "age": 54, "title": "Head of Global Marketing & Access", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lena  Bjurner", "age": 54, "title": "Head of HR", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Norbert  Oppitz", "age": 55, "title": "Head of International", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sofiane  Fahmy", "age": 50, "title": "Head of Europe", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Duane H. Barnes", "age": 62, "title": "Head of North America", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mahmood  Ladha", "age": 58, "title": "Head of Strategic Transformation Operations", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1682899200, "maxAge": 86400}}], "error": null}}